Corcept Therapeutics Incorporated (CORT)
NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous Close | 23.32 |
| Open | 23.09 |
| Bid | 23.74 x 800 |
| Ask | 23.87 x 100 |
| Day's Range | 22.60 - 24.61 |
| 52 Week Range | 20.84 - 34.28 |
| Volume | |
| Avg. Volume | 1,078,344 |
| Market Cap | 2.48B |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | 25.40 |
| EPS (TTM) | 0.94 |
| Earnings Date | Jul 31, 2024 - Aug 05, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 42.73 |
- GuruFocus.com
Corcept Therapeutics Inc (CORT) Q1 2024 Earnings Call Transcript Highlights: Strong Growth Amid ...
Corcept reports a robust financial performance and advances in clinical trials, despite facing potential generic competition.
GuruFocus.comCorcept Therapeutics Inc (CORT) Outperforms Analyst Estimates in Q1 2024
Revenue and Earnings Surge Amid Expanding Market Presence
GlobeNewswireCorcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update
MENLO PARK, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today reported its results for the quarter ended March 31, 2024. Financial Results Revenue of $146.8 million, a 39 percent increase over the same period in 2023Increase in 2024 revenue
© 2024 Yahoo. All rights reserved.